Urinary diversion

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively

Retrieved on: 
日曜日, 5月 5, 2024
UTI, Congress, FDA, FGFR, Cancer, Urinary diversion, Pyelonephritis, Erdafitinib, Hospital, Safety, Food, American Urological Association, Survival rate, FGFR3, Johnson & Johnson, Recurrence, Abstract, Cohort, BCG, PD-1, PD-L1, Disease, Bladder cancer, Patient, Medicine, AUA, Urinary bladder, MUC, Face, SAN, Sepsis, EAU, Pharmaceutical industry

SAN ANTONIO, May 5, 2024 /PRNewswire/ -- Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder, in patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations. These data were featured today in an Oral Presentation Session (Abstract # PD48-02) at the 2024 American Urological Association (AUA) Annual Meeting taking place May 3-6, 2024, in San Antonio, Texas.

Key Points: 
  • First results were featured at the European Society for Medical Oncology 2023 Congress, with interim results presented at the European Association of Urology (EAU) 2024 Annual Congress.
  • "Results presented today further underscore that TAR-210 for the localized treatment of bladder cancer may offer a promising alternative for patients with limited treatment options."
  • At the data cutoff of March 22, 2024, 64 patients had been treated with TAR-210 across the 2 cohorts.
  • Of the 21 patients in C1 with HR-NMIBC, the 12-month recurrence-free (RF) survival rate was 90%.

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer

Retrieved on: 
金曜日, 5月 3, 2024
FDA, Congress, Cancer, Urinary tract infection, Urinary diversion, Safety, Carcinoma, Survival, Johnson & Johnson, Immunotherapy, CRS, Abstract, Cohort, BCG, Disease, Bladder cancer, Dysuria, Patient, Metastasis, Medicine, NMIBC, AUA, Biopsy, BTD, Urination, Interim, Food and Drug Administration, SAN, Pharmaceutical industry

SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of investigational TAR-200 monotherapy in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ, who are ineligible for, or decline, radical cystectomy. These data were featured today in a plenary session (Abstract #P2-01) at the 2024 American Urological Association Annual Meeting (AUA) taking place May 3-6, 2024, in San Antonio, Texas.

Key Points: 
  • "These results address an area of high unmet need for bladder sparing therapies in this patient population."
  • Results included an evaluation of 85 patients (median age of 71 years old: range 40-88; 32.9% with concurrent papillary disease) who received TAR-200 monotherapy.
  • The centrally confirmed complete response (CR) rate was 82.8% by urine cytology and/or biopsy (95% confidence interval [CI], 70.6-91.4).
  • Seven patients (8.2%) had Grade 3 or higher TRAEs and four patients (4.7%) had one or more serious TRAEs.

Limmi appoints nationally recognized cancer researcher, Dr. Kader, to its Board of Directors

Retrieved on: 
火曜日, 3月 5, 2024
Advisory board, Doctor of Philosophy, MD, Urinary diversion, Bladder cancer, FRCSC, Genomics, Risk, Patient, Big data, UC San Diego Health, Deep learning, UCSD, Prostate cancer, Pharmaceutical industry

"We're in a desperate need at this time for solutions like the one Limmi is offering.

Key Points: 
  • "We're in a desperate need at this time for solutions like the one Limmi is offering.
  • states Professor Kader , and continues, "As a surgeon scientist, I made a discovery regarding genetic risk in prostate cancer.
  • In addition to being a board-certified urologist who specializes in detecting, treating, and preventing prostate cancer, Dr. Kader is nationally recognized for his expertise in performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer.
  • He holds several patents for genetic discoveries related to early detection of prostate cancer.

Penn Highlands Healthcare Physician Embraces Robotic Technology: First In Region To Robotically Remove a Bladder and Create a Urinary Diversion

Retrieved on: 
火曜日, 12月 5, 2023
Urine, General surgery, Bleeding, The Jetsons, Urethra, Lymph, Movement, Bladder cancer, Robotics, Male, Surgeon, Star Wars, Prostate cancer, Green-light, MD, Urinary diversion, Prostate, System, Ureteroscopy, Constriction, Prostatic urethral lift, Scar, Television, Cancer, Patient, Medicine, Female, R2-D2

Dr. Banerji recently completed his100th robotic case, which was a radical prostatectomy – surgery to remove the entire prostate gland and surrounding lymph nodes -- on a man with localized prostate cancer.

Key Points: 
  • In 2021, surgeons at Penn Highlands Healthcare began using the advanced da Vinci Xi robotic-assisted surgical system to perform a wide range of delicate and complex operations.
  • Today, in addition to being used for general surgery, the da Vinci robot is assisting surgeons who perform urologic, colorectal and gynecologic surgeries at Penn Highlands DuBois.
  • John S. Banerji, MD, a physician with Penn Highlands Urology in Clearfield and DuBois, Pennsylvania, has been using the robotic-assisted system for his surgeries.
  • While some surgeons remove the bladder robotically and then convert to open surgery for the urinary diversion, Dr. Banerji performed the entire surgical procedure robotically.